{"doi":"10.1016/j.metabol.2017.06.003","title":"Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications","abstract":null,"journal":"Metabolism","year":2017,"id":29761,"datarank":0.9824066491537645,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.5330468081206658,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.5330468081206658,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":11,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":163360,"name":"Christos S. Mantzoros","orcid":null,"position":1,"is_corresponding":false},{"id":163359,"name":"Stergios A. Polyzos","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28641789","pmcid":null,"openalex_id":"https://openalex.org/W2718920558","authors":[],"funders":[],"total_grants":0,"fwci":2.6458,"citation_percentile":0.90029995,"influential_citations":0,"citation_trend":[{"year":2017,"count":3},{"year":2018,"count":2},{"year":2019,"count":5},{"year":2020,"count":2},{"year":2022,"count":1},{"year":2023,"count":2},{"year":2024,"count":1},{"year":2025,"count":3}],"oa_status":"bronze","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"http://www.metabolismjournal.com/article/S0026049517301609/pdf","host_type":"journal"},{"url":"http://www.metabolismjournal.com/article/S0026049517301609/pdf","host_type":"BRONZE"},{"url":"http://www.metabolismjournal.com/article/S0026049517301609/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0026049517301609?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0026049517301609?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.metabol.2017.06.003","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28641789","host_type":"repository"}],"fields_of_study":["Diabetes and associated disorders","Nuclear Structure and Function","Adipokines, Inflammation, and Metabolic Diseases","Medicine","Cost-Benefit Analysis","Humans","Leptin","Lipodystrophy","Randomized Controlled Trials as Topic","Registries"],"mesh_terms":["Cost-Benefit Analysis","Humans","Lipodystrophy","Registries","Randomized Controlled Trials as Topic","Leptin"],"keywords":["Lipodystrophy","Lipoatrophy","Medicine","Antiretroviral therapy","Adipose tissue","Human immunodeficiency virus (HIV)","Clinical trial","Internal medicine","Pediatrics","Immunology","Viral load","Leptin","Adipokine","Familial Partial Lipodystrophy","Metreleptin"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-09T00:40:50.840186Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}